Impact of COVID-19 on Oncology Clinical Trials
Nature
The survey results indicate that patient enrolment in active oncology clinical trials was negatively affected at the time of the survey, especially in the United States and Europe, with only 20% or 14% of the institutions continuing to enroll patients at the usual rate in these two regions, respectively. For institutions engaged in trials that were continuing, but with lower enrollment rates, patient care (as reflected by a comparison between in-patient and outpatient settings) was a key factor, with 9 out of 13 respondents identifying it as one of the top three considerations causing the most difficulty for patient enrollment in ongoing trials. The type of cancer therapy, including route of administration, was another key consideration.
